Ensuring safety, quality, and long‑term genetic stability of allogeneic iPSC banks for cell therapy drug products

Induced pluripotent stem cell (iPSC)-derived cell therapy products have shown great promise for the treatment of various diseases, ranging from cancer, autoimmune diseases, and other B cell malignancies to Type I diabetes and Parkinson’s disease. While the nature of pluripotent stem cells as a starting material for production of a wide range of differentiated cell drug products is powerful, it also warrants a high degree of control and characterization to ensure unintended consequences during the manufacturing process are not realized. For allogenic iPSC products, safety, quality, and other key attributes must be monitored as early as initial donor screening and continue through cellular reprogramming, genetic engineering, master cell bank (MCB) generation, and final drug product. Utilization of various traditional and next‑generation technologies for evaluation of phenotype, genetic stability, tumorigenicity risk, impact of residual cells, and other safety‑related properties is critical and expected by regulatory bodies for product development.

Ensuring safety, quality, and long-term genetic stability of allogeneic iPSC banks requires monitoring at every stage — from donor screening and reprogramming through genetic engineering, master cell bank generation, and final drug product characterisation.

What you will learn

01

How traditional and next-generation technologies characterise iPSC safety and genetic stability

02

What analytical methods are used for release, characterisation, and stability testing at each banking stage

03

How residual iPSCs and tumorigenicity risk are assessed downstream to confirm drug product safety

The iPSC quality control pathway

1

Donor screening & eligibility

21 CFR Part 1241 criteria

2

Reprogramming & initial iPSC testing

Safety, identity & purity

3

Genetic engineering & characterisation

HLA editing, CARs, OGM, WGS

4

MCB / WCB generation & release

Full QC testing panel

5

Downstream safety confirmation

ddPCR & tumorigenicity studies

Key findings

Optical genome mapping (OGM) offers higher-resolution karyotyping and multiplexed donor identity confirmation from a single sample, outperforming traditional G-banding and STR analysis

Cumulative genomic manipulations increase the risk of undesired variants; whole genome sequencing is now a central regulatory expectation for IND submissions

ddPCR-based residual iPSC detection using mRNA/miRNA signatures enables single-cell sensitivity — critical for preventing teratoma formation in allogeneic drug products

End-of-production (EOP) cell banks serve as a final stability checkpoint, with iPSC banks potentially in use for 5 years or more, necessitating robust long-term stability study designs

Key interests

Cell Therapy

Gene Therapy

iPSC Banking

Genetic Stability

Quality Control

Regulatory Compliance

Read the full article below